アブストラクト | INTRODUCTION: This retrospective claims analysis characterized contemporary ulcerative colitis (UC) treatment patterns and investigated the economic burden of UC in Japan. METHODS: This study used anonymized claims data in the Medical Data Vision database. Patients were included if they had a confirmed UC diagnosis and >/= 1 claim of systemic treatment for UC (index date) between June 2018 and December 2022, in addition to continuous enrollment for >/= 6 months before and >/= 12 months after the index date. Patients were excluded if they were aged < 18 years at index or if they had claimed systemic UC treatment during the pre-index period, had a confirmed diagnosis of Crohn's or Behcet's disease, or had a record of colectomy during the pre-index period. Outcomes of interest were treatment patterns, healthcare resource utilization (HCRU), and UC-related costs per person per month (PPPM). Further exploratory analyses were conducted to understand whether real-world treatment patterns with conventional therapy were optimally aligned with guideline recommendations. Two definitions of suboptimal treatment with conventional therapies were identified: prolonged treatment with corticosteroids (i.e., consecutive use for > 90 days) and corticosteroid cycling (i.e., three or more >/= 30-day corticosteroid courses over 1 year, with a >/= 60-day gap between courses). RESULTS: Overall, 15,429 patients were included. The most frequently observed class of first-line treatment was 5-aminosalicylic acid monotherapy (75.0%); treatment modification was observed in 39.7% of patients. Within 1 year of follow-up, patients had a mean (SD) of 9.8 (6.8) outpatient visits, and a hospital stay was reported in 23.9% of patients. Mean total cost PPPM was yen76,374. Of patients with >/= 1 course of corticosteroids, 39.8% received suboptimal treatment with conventional therapies. HCRU and total costs were higher for patients with versus without suboptimal treatment with conventional therapies. CONCLUSIONS: Japanese patients with UC would benefit from treatment options that can reduce costs, HCRU, and suboptimal treatment with conventional therapies. |
ジャーナル名 | Advances in therapy |
Pubmed追加日 | 2025/1/24 |
投稿者 | Kato, Shingo; Teixeira, Bruno Casaes; Laurent, Thomas; Yamada, Yoshiyuki; Dave, Kiran; Shah, Shweta; Kim, Hyunchung |
組織名 | Saitama Medical Center, Saitama Medical University, Saitama, Japan.;Bristol Myers Squibb, London, UK.;Bristol Myers Squibb, 1-2-1 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan.;Bristol Myers Squibb, Princeton, NJ, USA.;ray.kim@bms.com. |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39853657/ |